| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Dimitrios Pectasides | |
| Amanda Psyrri | |||
| Eirini Pectasides | |||
| Theofanis Economopoulos | |||
| P433 | issue | 10 | |
| P921 | main subject | clear cell carcinoma | Q18556242 |
| P304 | page(s) | 1089-1094 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Treatment issues in clear cell carcinoma of the ovary: a different entity? | |
| P478 | volume | 11 |
| Q33634277 | A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer |
| Q47235553 | Body size and risk of epithelial ovarian and related cancers: a population-based case-control study |
| Q45933729 | Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. |
| Q58779796 | Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor |
| Q35870176 | Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary |
| Q28265125 | Clear cell carcinoma of the ovary: a review of the literature |
| Q53506540 | Clinical manifestations in patients with ovarian clear cell carcinoma with or without co-existing endometriosis. |
| Q35612005 | Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach |
| Q33647555 | HNF-1β in ovarian carcinomas with serous and clear cell change |
| Q56334183 | Histotype classification of ovarian carcinoma: A comparison of approaches |
| Q28742873 | Identification of novel therapeutic targets in microdissected clear cell ovarian cancers |
| Q47123431 | Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target |
| Q34990141 | Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis |
| Q52596252 | Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. |
| Q52714804 | Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. |
| Q33305690 | Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma |
| Q35686765 | Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers |
| Q35687723 | Magnetic Resonance Imaging Characteristics of Ovarian Clear Cell Carcinoma |
| Q46879650 | Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. |
| Q84271936 | Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis |
| Q37988298 | Prognostic determinants in patients with uterine and ovarian clear carcinoma |
| Q40112859 | Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study |
| Q83414403 | Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers |
| Q36622857 | Recent progress in the diagnosis and treatment of ovarian cancer |
| Q55163731 | Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer. |
| Q36546449 | Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers |
| Q41777292 | Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease |
| Q37665204 | Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma |
| Q99418333 | Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma |
| Q37396993 | The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. |
| Q42371676 | The miR-200 family in ovarian cancer. |
| Q35771750 | The promise and challenge of ovarian cancer models |
| Q39344635 | Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer |
| Q37269461 | Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review). |
| Q37335723 | Two cases of clear cell ovarian cancer in young patients |
| Q34436363 | miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells |
Search more.